Jagsonpal Pharmaceuticals Limited
JAGSNPHARM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹151.19.
Investability checklist
- ✓ROE above 15%16.7%
- ✓Low debt (D/E < 0.5)0.03x
- ✓Positive free cash flow
- ✕Revenue growth > 10%10%
- ✓Earnings growing24%
- ✓Net margin ≥ 10%15.0%
- ✓Current ratio > 1.55.06
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- –Piotroski ≥ 7
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
Opportunities
- •Earnings growing (24% YoY).
- •Trading in our value buy zone versus sector peers.
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.